Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $16,581,855.02 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 26,701 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $621.02, for a total transaction of $16,581,855.02. Following the completion of the sale, the chief executive officer directly owned 360,191 shares in the company, valued at $223,685,814.82. This trade represents a 6.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Medpace Stock Performance

Shares of MEDP stock opened at $599.47 on Friday. The stock has a market capitalization of $16.73 billion, a P/E ratio of 35.14, a price-to-earnings-growth ratio of 2.67 and a beta of 1.18. The company has a 50 day moving average price of $599.95 and a 200 day moving average price of $521.18. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue was up 17.2% on a year-over-year basis. During the same period last year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace from “sell” to “hold” and raised its price target to $673 from $405. The new target is above recent trading levels, suggesting UBS sees reduced downside risk. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace’s latest quarterly results remain supportive of its growth story: revenue rose 17.2% year over year to $707.3 million, while earnings of $4.25 per share exceeded the $3.98 consensus estimate. Fiscal 2026 earnings guidance also remains intact.
• Neutral Sentiment: Analyst sentiment is broadly mixed, with most firms maintaining “hold” ratings. The consensus price target is approximately $602.27, close to recent levels, indicating that much of the company’s growth may already be reflected in its valuation.
• Negative Sentiment: CEO August Troendle sold 21,966 shares for approximately $13.7 million on September 30, after selling 26,701 shares worth about $16.6 million on September 29. The combined sales totaled roughly $30.3 million and materially reduced his direct ownership. Additional smaller sales were also reported, raising concerns about insider confidence and contributing to the stock’s weakness. Troendle nevertheless retains a substantial stake. Medpace CEO stock sale SEC filing

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cim Investment Management Inc. raised its stake in shares of Medpace by 7.3% in the 2nd quarter. Cim Investment Management Inc. now owns 1,137 shares of the company’s stock worth $602,000 after buying an additional 77 shares in the last quarter. State Street Corp boosted its stake in Medpace by 4.2% during the second quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after buying an additional 28,666 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Medpace by 38.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock worth $10,615,000 after acquiring an additional 5,610 shares during the period. Sequoia Financial Advisors LLC raised its position in Medpace by 8.2% in the second quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company’s stock worth $587,000 after acquiring an additional 84 shares in the last quarter. Finally, Tidal Investments LLC raised its position in Medpace by 8.0% in the second quarter. Tidal Investments LLC now owns 6,155 shares of the company’s stock worth $3,260,000 after acquiring an additional 458 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MEDP shares. Truist Financial upped their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a research note on Monday, September 14th. UBS Group assumed coverage on shares of Medpace in a research report on Wednesday. They set a “neutral” rating and a $673.00 price target on the stock. Mizuho increased their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus target price of $602.27.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.